Lantern Pharma Inc. Unrealized Gain (Loss) on Investments
Lantern Pharma Inc. (LTRN) reported Unrealized Gain (Loss) on Investments of -$32.21 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-14
- Lantern Pharma Inc. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $27.24K, a 68.92% increase year-over-year.
- Lantern Pharma Inc. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$59.45K, a 139.30% decline year-over-year.
- Lantern Pharma Inc. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $42.59K.
- Lantern Pharma Inc. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $95.91K, a 56.98% decline year-over-year.
- Lantern Pharma Inc. unrealized gain (loss) on investments for fiscal 2025 was $305.89K, a 96.56% increase from fiscal 2024.
- Lantern Pharma Inc. unrealized gain (loss) on investments for fiscal 2024 was $155.62K, a 30.07% increase from fiscal 2023.
- Lantern Pharma Inc. unrealized gain (loss) on investments for fiscal 2023 was $119.65K.
- Lantern Pharma Inc. unrealized gain (loss) on investments for fiscal 2022 was -$492.50K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$32.21K 10-Q · filed 2026-08-14 | $10.38K derived: sum of 3 quarters · filed 2026-08-14 | $106.28K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$59.45K 10-Q · filed 2026-05-15 | -$16.86K derived: sum of 2 quarters · filed 2026-05-15 | $79.05K derived: sum of 3 quarters · filed 2026-05-15 | $95.17K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $42.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $138.50K derived: sum of 2 quarters · filed 2026-03-30 | $154.62K derived: sum of 3 quarters · filed 2026-08-14 | $305.89K 10-K · filed 2026-03-30 |
| 2025-09-30 | $95.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $112.03K derived: sum of 2 quarters · filed 2026-08-14 | $263.30K 10-Q · filed 2025-11-12 | $197.79K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $16.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $167.39K 10-Q · filed 2026-08-14 | $101.89K derived: sum of 3 quarters · filed 2026-08-14 | $324.81K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $151.26K 10-Q · filed 2026-05-15 | $85.76K derived: sum of 2 quarters · filed 2026-05-15 | $308.69K derived: sum of 3 quarters · filed 2026-05-15 | $302.94K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$65.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $157.42K derived: sum of 2 quarters · filed 2026-03-30 | $151.67K derived: sum of 3 quarters · filed 2026-03-30 | $155.62K 10-K · filed 2026-03-30 |
| 2024-09-30 | $222.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $217.17K derived: sum of 2 quarters · filed 2025-11-12 | $221.12K 10-Q · filed 2025-11-12 | $358.07K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.80K 10-Q · filed 2025-08-13 | $135.15K derived: sum of 3 quarters · filed 2025-08-13 | $105.80K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $3.95K 10-Q · filed 2025-05-15 | $140.90K derived: sum of 2 quarters · filed 2025-05-15 | $111.55K derived: sum of 3 quarters · filed 2025-05-15 | $81.45K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $136.95K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $107.60K derived: sum of 2 quarters · filed 2025-03-27 | $77.50K derived: sum of 3 quarters · filed 2025-03-27 | $119.65K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$29.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$59.45K derived: sum of 2 quarters · filed 2024-11-07 | -$17.30K 10-Q · filed 2024-11-07 | -$33.05K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$30.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $12.05K 10-Q · filed 2024-08-08 | -$3.70K derived: sum of 3 quarters · filed 2024-08-08 | -$123.35K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $42.15K 10-Q · filed 2024-05-09 | $26.40K derived: sum of 2 quarters · filed 2024-05-09 | -$93.25K derived: sum of 3 quarters · filed 2024-05-09 | -$254.40K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$15.75K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$135.40K derived: sum of 2 quarters · filed 2024-03-18 | -$296.55K derived: sum of 3 quarters · filed 2024-03-18 | -$492.50K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$119.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$280.80K derived: sum of 2 quarters · filed 2023-11-08 | -$476.75K 10-Q · filed 2023-11-08 | -$542.40K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$161.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$357.10K 10-Q · filed 2023-08-09 | -$422.75K derived: sum of 3 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$195.95K 10-Q · filed 2023-05-09 | -$261.60K derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$65.65K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$80.56K 10-K · filed 2023-03-20 | ||
| 2021-09-30 | -$14.91K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |